Simplify Asset Management Inc. Boosts Stock Holdings in Milestone Pharmaceuticals Inc. $MIST

Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 186.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,832,974 shares of the company’s stock after purchasing an additional 1,842,974 shares during the period. Milestone Pharmaceuticals accounts for approximately 0.1% of Simplify Asset Management Inc.’s portfolio, making the stock its 29th largest holding. Simplify Asset Management Inc. owned 3.33% of Milestone Pharmaceuticals worth $5,666,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Sapient Capital LLC purchased a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $25,000. Bay Rivers Group purchased a new stake in Milestone Pharmaceuticals during the second quarter valued at about $28,000. Creative Planning boosted its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the period. Walleye Capital LLC purchased a new position in shares of Milestone Pharmaceuticals in the first quarter worth about $74,000. Finally, Raymond James Financial Inc. raised its position in shares of Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after purchasing an additional 10,000 shares during the period. 86.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 22nd. Wells Fargo & Company raised their price target on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Wall Street Zen raised Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Milestone Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Milestone Pharmaceuticals Trading Down 1.9%

Milestone Pharmaceuticals stock opened at $2.04 on Tuesday. The stock has a market cap of $173.75 million, a P/E ratio of -2.49 and a beta of 0.40. Milestone Pharmaceuticals Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.06. The firm’s fifty day moving average price is $2.20 and its 200-day moving average price is $1.95. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.05. Equities research analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Milestone Pharmaceuticals Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.